Answer from: at Academic Institution
My “top 3” takeaways from ACC23 are;
CLEAR Outcomes trial which demonstrated that bempedoic acid reduced LDL by about 20% and improves long-term CV outcomes compared with placebo among patients with established ASCVD or high risk for it, and intolerance to statin therapy (though a minor...
Sign in or Register to read more
Answer from: at Academic Institution
The main trials I would say:
IVUS-guided intervention vs Angiography
Anticoagulation and COVID
Exercise and Cardiomyopathy
Answer from: at Academic Institution
3 major trials in structural heart disease were presented at ACC:
TRILUMINATE RCT of medical therapy vs transcatheter edge-to-edge repair in patients with severe symptomatic tricuspid regurgitation. A key finding is that transcatheter repair was (a) effective in reducing tricuspid regurgitation (87...